Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.
The company believes that blood-based exome sequencing can increase the applicability of its Signatera assays and could serve as a reflex to interrogate detected recurrences.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
Clinical trials investigating whether epigenetic treatment can restore susceptibility to other treatments are underway in colorectal, lung, and breast cancers.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.
Biocept will use its liquid biopsy assay to test cerebrospinal fluids of patients diagnosed with certain cancers and then compare results to standard methods.
